• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Abilify (aripiprazole)

Audience: Neuropsychiatric healthcare professionals

FDA and Bristol-Myers Squibb notified healthcare professionals of revision to the WARNINGS section of labeling, describing the risk of hyperglycemia and diabetes in patients taking Abilify. FDA asked all manufacturers of atypical antipsychotic medications, including Bristol-Myers Squibb, to add this Warning statement to labeling.

[March 25, 2004 - Letter - FDA]
[March, 2004 - Revised label - Bristol-Myers Squibb]